Thrombocytopenia-associated multiple organ failure (TAMOF) is a poorly understood syndrome in critically ill children. ADAMTS-13, formerly known as von Willebrand factor (VWF) cleaving protease, is decreased in adults with VWF mediated thrombotic microangiopathy, and intensive plasma exchange (PEx) both replenishes ADAMTS-13 and improves outcome in these patients. We hypothesized that children with TAMOF syndrome have decreased ADAMTS-13 activity which can be replenished with PEx. In the first of two consecutive studies, relationships between platelet count, VWF multimers, ADAMTS-13 activity, plasminogen activator inhibitor-1 (PAI-1) and prothrombin time (PT) were analyzed in children with and without TAMOF. In the second study, children with severe TAMOF (platelet counts<100,000/mm3 and ≥3 organ failure) were randomized to PEx or standard therapy. In the first study, children with TAMOF (n=28) had decreased ADAMTS-13 activity, but similar PAI-1 activity and PT compared to children with MOF without thrombocytopenia (n=9) (p<0.05). All non-survivors (n=7) had TAMOF, reduced ADAMTS 13 activity, and VWF-rich microvascular thromboses at autopsy. In the second study, PEx (n=5, median 12 days, 4–28 days) restored ADAMTS-13 activity and organ function, compared to standard therapy (n=5) (p<0.05). Children with TAMOF syndrome can have VWF mediated thrombotic microangiopathy. Similar to adult experience, PEx can replenish ADAMTS-13 activity and reverse organ failure in these children.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.